{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:44:45Z","timestamp":1790239485124,"version":"4.1.0"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            High treatment failure rates for\n            <jats:named-content content-type=\"genus-species\">Plasmodium falciparum<\/jats:named-content>\n            malaria have been reported in Colombia for chloroquine, amodiaquine, and sulfadoxine-pyrimethamine. Artemisinin combination therapies were introduced in 2006 in Colombia, where artemether-lumefantrine (AL) is currently used to treat uncomplicated\n            <jats:named-content content-type=\"genus-species\">P. falciparum<\/jats:named-content>\n            malaria. Artemisinin (ART) resistance was initially observed in Southeast Asia as an increased parasite clearance time, manifesting as a positive thick-blood smear on day 3 after treatment (D3 positivity). Recently, mutations in the propeller domain of the\n            <jats:named-content content-type=\"genus-species\">P. falciparum<\/jats:named-content>\n            <jats:italic>kelch13<\/jats:italic>\n            gene (\n            <jats:italic>K13<\/jats:italic>\n            propeller) have been associated with ART resistance. In this study, we surveyed AL effectiveness at D3 and molecular markers of drug resistance among 187 uncomplicated\n            <jats:named-content content-type=\"genus-species\">P. falciparum<\/jats:named-content>\n            cases in 4 regions of Colombia from June 2014 to July 2015. We found that 3.2% (4\/125) of patients showed D3 positivity, 100% (163\/163) of isolates carried wild-type\n            <jats:italic>K13<\/jats:italic>\n            propeller alleles, 12.9% (23\/178) of isolates had multiple copies of the multidrug resistance 1 gene (\n            <jats:italic>mdr1<\/jats:italic>\n            ), and 75.8% (113\/149) of isolates harbored the double mutant N\n            <jats:underline>F<\/jats:underline>\n            S\n            <jats:underline>D<\/jats:underline>\n            D\n            <jats:italic>mdr1<\/jats:italic>\n            haplotype (the underlining indicates mutant alleles). These data suggest that ART resistance is not currently suspected in Colombia but that monitoring for lumefantrine resistance and AL failures should continue.\n          <\/jats:p>","DOI":"10.1128\/aac.01036-17","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:40:22Z","timestamp":1506386422000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["<i>K13<\/i>\n            Propeller Alleles,\n            <i>mdr1<\/i>\n            Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015"],"prefix":"10.1128","volume":"61","author":[{"given":"Madeline","family":"Montenegro","sequence":"first","affiliation":[{"name":"Grupo Malaria, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Neal","sequence":"additional","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Posada","sequence":"additional","affiliation":[{"name":"Grupo Malaria, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briegel","family":"De las Salas","sequence":"additional","affiliation":[{"name":"Grupo Malaria, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana M.","family":"Lopera-Mesa","sequence":"additional","affiliation":[{"name":"Grupo Malaria, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick M.","family":"Fairhurst","sequence":"additional","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tobon-Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Grupo Malaria, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Boletin epidemiologico semana 52","author":"Instituto Nacional de Salud","year":"2015","unstructured":"Instituto Nacional de Salud. 2015. Boletin epidemiologico semana 52. Instituto Nacional de Salud, Bogot\u00e1, Colombia. http:\/\/www.ins.gov.co\/boletin-epidemiologico\/Boletn%20Epidemiolgico\/2015%20Boletin%20epidemiologico%20Semana%2052.pdf."},{"key":"e_1_3_3_3_2","volume-title":"Boletin epidemiol\u00f3gico semana 51","author":"Instituto Nacional de Salud","year":"2014","unstructured":"Instituto Nacional de Salud. 2014. Boletin epidemiol\u00f3gico semana 51. Instituto Nacional de Salud, Bogot\u00e1, Colombia. http:\/\/www.ins.gov.co\/boletin-epidemiologico\/Boletn%20Epidemiolgico\/2014%20Boletin%20epidemiologico%20Semana%2051.pdf."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-5-14"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.61.968"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7705\/biomedica.v29i2.32"},{"key":"e_1_3_3_7_2","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805011"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808859"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314981"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70181-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70252-4"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12876"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.EI10-0013-2016"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-125"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-339"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020212"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01243-09"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.241"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0192"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trx021"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0843-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0031"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0017"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu467"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08714"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-06"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-25"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1998.58.630"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01677-08"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12118"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw388"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.1034"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-14-2"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-1018-3"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.7705\/biomedica.v27i2.216"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182008004307"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01790-12"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-73"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2012.12.014"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01304-09"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03494-14"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/503423"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.11-0250"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-43"},{"key":"e_1_3_3_46_2","unstructured":"Pan American Health Organization. 2010. Gu\u00eda para la atenci\u00f3n cl\u00ednica integral del paciente con malaria. http:\/\/www.paho.org\/col\/index.php?option=com_docman&view=download&category_slug=publicaciones-ops-oms-colombia&alias=1220-guia-para-la-atencion-clinica-integral-del-paciente-con-malaria&Itemid=688."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(93)90077-B"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-13"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/345255a0"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01036-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01036-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:47:07Z","timestamp":1645476427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01036-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1128\/AAC.01036-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01036-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"2017-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01036-17"}}